alexa Management Of Psoriasis Patients Treated With Infliximab Based On The Dynamics Of Infliximab Levels And Antibodies To Infliximab | 16354
ISSN: 2155-9554

Journal of Clinical & Experimental Dermatology Research
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

4th International Conference on Clinical & Experimental Dermatology

Andrea Kovacikova Curkova, Peter Kozub and Maria Simaljakova
ScientificTracks Abstracts: J Clin Exp Dermatol Res
DOI: 10.4172/2155-9554.C1.013
Abstract
Infliximab is the fastest acting biologic agent due to intravenous administration and a well-conducted induction phase of treatment. The disadvantages include the risk of infusion reactions and the production of neutralizing antibodies that are responsible for loss of efficacy. The authors enrolled 30 patients with psoriasis treated with infliximab for a period of minimum 1 year at a dose of 5 mg/kg. Based on the clinical picture the patients were divided into responders (almost clear), partial responders (gradual appearance of new lesions towards the last weeks), and non-responders. Levels of infliximab and antibodies to infliximab were examined in venous blood samples taken in one maintenance interval. Infliximab levels were examined in week 0 (before infusion) and later in weeks 2, 4, 6, 7, and 8 of the maintenance interval. Antibodies to infliximab were examined only in week 8. According to the obtained data, we divided the patients into 4 groups - responders, responders with shortened period of efficacy, non-responders with production of antibodies, and non-responders without production of antibodies. The dynamics of infliximab levels and the production of antibodies to infliximab were characteristic for each group. An exact therapeutic management was created specifically for each group of patients. Monitoring of the dynamics of infliximab levels and antibodies to infliximab is not only of scientific importance, but it may be crucial in daily clinical practice enabling an objective management of infliximab treatment
Biography

Andrea Kovacikova Curkova is a European board certified dermato-venerologist since 2012. She has completed her residency in dermatology and venerology at the Department of Dermatology and Venerology, Comenius University Faculty of Medicine, Bratislava, Slovakia. She is in her last year of Ph.D. at Comenius University Faculty of Medicine in Bratislava with the research topic Psoriasis and Comorbidities. She is involved in various research projects on psoriasis in the role of a sub-investigator. She has been active in presenting lectures at national and international meetings. She has published 5 papers in reputed journals and won multiple awards for young dermatologists.

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7